Fox Run Management L.L.C. Takes Position in Intuitive Surgical, Inc. $ISRG

Fox Run Management L.L.C. bought a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,824 shares of the medical equipment provider’s stock, valued at approximately $1,263,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Intuitive Surgical by 24.9% in the fourth quarter. Brighton Jones LLC now owns 3,672 shares of the medical equipment provider’s stock valued at $1,916,000 after buying an additional 731 shares during the last quarter. Sivia Capital Partners LLC increased its position in Intuitive Surgical by 3.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 928 shares of the medical equipment provider’s stock valued at $504,000 after acquiring an additional 34 shares during the period. Schnieders Capital Management LLC. raised its stake in Intuitive Surgical by 38.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 973 shares of the medical equipment provider’s stock valued at $529,000 after acquiring an additional 268 shares during the last quarter. Rossby Financial LCC lifted its position in Intuitive Surgical by 55.1% during the 2nd quarter. Rossby Financial LCC now owns 304 shares of the medical equipment provider’s stock worth $165,000 after acquiring an additional 108 shares during the period. Finally, Advisory Alpha LLC grew its stake in shares of Intuitive Surgical by 7.0% in the 2nd quarter. Advisory Alpha LLC now owns 2,253 shares of the medical equipment provider’s stock valued at $1,224,000 after purchasing an additional 147 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity

In other Intuitive Surgical news, VP Fredrik Widman sold 133 shares of Intuitive Surgical stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $494.96, for a total value of $65,829.68. Following the completion of the sale, the vice president owned 660 shares in the company, valued at $326,673.60. The trade was a 16.77% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Brosius sold 464 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $548.49, for a total transaction of $254,499.36. Following the completion of the sale, the senior vice president owned 131 shares of the company’s stock, valued at approximately $71,852.19. The trade was a 77.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 56,189 shares of company stock valued at $30,785,441. 0.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ISRG has been the subject of several analyst reports. Royal Bank Of Canada upped their price target on Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. BTIG Research restated a “buy” rating and set a $616.00 price objective on shares of Intuitive Surgical in a research report on Friday, January 23rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Intuitive Surgical in a report on Monday, December 29th. Wells Fargo & Company boosted their price target on shares of Intuitive Surgical from $600.00 to $654.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Finally, Sanford C. Bernstein raised their price objective on shares of Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $615.86.

Intuitive Surgical Price Performance

ISRG opened at $506.17 on Thursday. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $603.88. The stock has a market cap of $179.76 billion, a P/E ratio of 64.15, a P/E/G ratio of 3.83 and a beta of 1.65. The stock’s 50 day simple moving average is $532.31 and its 200 day simple moving average is $511.29.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, January 22nd. The medical equipment provider reported $2.53 EPS for the quarter, beating analysts’ consensus estimates of $2.27 by $0.26. The firm had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The firm’s revenue was up 18.8% on a year-over-year basis. During the same period in the prior year, the company earned $2.21 EPS. Research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.